Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry

JACC: Cardiovascular Interventions

Volumn 9, Issue 13, 2016, Pages 1349-1357

  Baber, Usman ^a   Dangas, George ^a   Chandrasekhar, Jaya ^a   Sartori, Samantha ^a   Steg, Philippe Gabriel ^b   Cohen, David J ^c   Giustino, Gennaro ^a   Ariti, Cono ^d   Witzenbichler, Bernhard ^e   Henry, Timothy D ^f   Kini, Annapoorna S ^a   Krucoff, Mitchell W ^g   Gibson, C Michael ^h   Chieffo, Alaide ⁱ   Moliterno, David J ^j   Weisz, Giora ^k   Colombo, Antonio ⁱ   Pocock, Stuart ^d   Mehran, Roxana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e Helios Amper Klinikum   (Germany)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j UNIVERSITY OF KENTUCKY   (United States)

^k SHAARE ZEDEK MEDICAL CENTER   (Israel)

more..

Author keywords

bleeding; dual antiplatelet therapy; mortality

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN; THIENOPYRIDINE DERIVATIVE; ANTITHROMBOCYTIC AGENT;

ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR STENT; CAUSE OF DEATH; CORONARY ARTERY THROMBOSIS; DISEASE ASSOCIATION; DUAL ANTIPLATELET THERAPY; FEMALE; FOLLOW UP; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RISK; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STENT THROMBOSIS; ADVERSE EFFECTS; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CORONARY THROMBOSIS; DEVICES; DIAGNOSTIC IMAGING; EUROPE; HEMORRHAGE; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; RISK FACTOR; STENT; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84990869192     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2016.04.009     Document Type: Article

References (31)

1. 1 Kikkert, W.J., Zwinderman, A.H., Vis, M.M., et al. Timing of mortality after severe bleeding and recurrent myocardial infarction in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 6 (2013), 391–398.
2. 2 Mehran, R., Pocock, S.J., Stone, G.W., et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 30 (2009), 1457–1466.
3. 3 Wenaweser, P., Daemen, J., Zwahlen, M., et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-Year results from a large 2-institutional cohort study. J Am Coll Cardiol 52 (2008), 1134–1140.
4. 4 Kim, Y.H., Lee, J.Y., Ahn, J.M., et al. Impact of bleeding on subsequent early and late mortality after drug-eluting stent implantation. J Am Coll Cardiol Intv 4 (2011), 423–431.
5. 5 Collet, J.P., Silvain, J., Barthelemy, O., et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 384 (2014), 1577–1585.
6. 6 Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
7. 7 Park, S.J., Park, D.W., Kim, Y.H., et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 362 (2010), 1374–1382.
8. 8 Feit, F., Voeltz, M.D., Attubato, M.J., et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol 100 (2007), 1364–1369.
9. 9 Manoukian, S.V., Feit, F., Mehran, R., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. J Am Coll Cardiol 49 (2007), 1362–1368.
10. 10 Ndrepepa, G., Schuster, T., Hadamitzky, M., et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 125 (2012), 1424–1431.
11. 11 Mehran, R., Pocock, S.J., Nikolsky, E., et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 55 (2010), 2556–2566.
12. 12 Antman, E.M., Cohen, M., Bernink, P.J., et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284 (2000), 835–842.
13. 13 Meisinger, C., Doring, A., Lowel, H., Group, K.S., Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 27 (2006), 1245–1250.
14. 14 Mehran, R., Baber, U., Steg, P.G., et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 382 (2013), 1714–1722.
15. 15 Cutlip, D.E., Windecker, S., Mehran, R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
16. 16 Thygesen, K., Alpert, J.S., White, H.D., et al. Universal definition of myocardial infarction. Circulation 116 (2007), 2634–2653.
17. 17 Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
18. 18 Platt, R.W., Joseph, K.S., Ananth, C.V., Grondines, J., Abrahamowicz, M., Kramer, M.S., A proportional hazards model with time-dependent covariates and time-varying effects for analysis of fetal and infant death. Am J Epidemiol 160 (2004), 199–206.
19. 19 Therneau, T.M., Grambsch, P.M., Modeling Survival Data: Extending the Cox Model. 2000, Springer-Verlag, New York.
20. 20 Chhatriwalla, A.K., Amin, A.P., Kennedy, K.F., et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 309 (2013), 1022–1029.
21. 21 Kazi, D.S., Leong, T.K., Chang, T.I., Solomon, M.D., Hlatky, M.A., Go, A.S., Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention. J Am Coll Cardiol 65 (2015), 1411–1420.
22. 22 Kirtane, A.J., Sandhu, P., Mehran, R., et al. Association between intraprocedural thrombotic events and adverse outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (a Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] substudy). Am J Cardiol 113 (2014), 36–43.
23. 23 Rao, S.V., Dai, D., Subherwal, S., et al. Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. J Am Coll Cardiol Intv 5 (2012), 958–965.
24. 24 Budaj, A., Eikelboom, J.W., Mehta, S.R., et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 30 (2009), 655–661.
25. 25 Lindsey, J.B., Marso, S.P., Pencina, M., et al. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) registry. J Am Coll Cardiol Intv 2 (2009), 1074–1082.
26. 26 Ndrepepa, G., Berger, P.B., Mehilli, J., et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51 (2008), 690–697.
27. 27 Rich, J.D., Cannon, C.P., Murphy, S.A., Qin, J., Giugliano, R.P., Braunwald, E., Prior aspirin use and outcomes in acute coronary syndromes. J Am Coll Cardiol 56 (2010), 1376–1385.
28. 28 Cheng, X., Chen, W.H., Simon, D.I., Aspirin resistance or variable response or both?. Am J Cardiol 98 (2006), 11N–17N.
29. 29 Berger, J.S., Bhatt, D.L., Steg, P.G., et al. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 162 (2011), 98–105.
30. 30 Vranckx, P., Leonardi, S., Tebaldi, M., et al. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. Eur Heart J 35 (2014), 2524–2529.
31. 31 Yeh R. Individualizing treatment duration of dual antiplatelet therapy after percutaneous coronary intervention: an analysis from the DAPT study. Presented at: American Heart Association Scientific Sessions; November 10, 2015; Orlando, FL.